PR is a 45 y/o male that has been recently diagnosed with early stages of Parkinson's Disease. You put PR on a dopaminergic agent (dopamine agonist), which of the following agents is an appropriate first line treatment? Select one:

Parkinson’s disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra of the brain. This dopamine deficiency leads to motor symptoms such as tremors, rigidity, bradykinesia, and postural instability. In the early stages, treatment often focuses on improving dopaminergic activity to control symptoms and preserve function. Dopamine agonists are commonly used as first-line therapy in younger patients to delay the need for levodopa therapy. Rationale: A. Neostigmine (Prostigmin) is a cholinesterase inhibitor primarily used to treat myasthenia gravis, postoperative urinary retention, and reversal of nondepolarizing neuromuscular blockers. It increases acetylcholine levels at the neuromuscular junction rather than enhancing dopamine activity in the brain. Since Parkinson’s disease results from dopamine deficiency, neostigmine does not address the underlying pathology. B. Physostigmine (Antilirium) is another cholinesterase inhibitor used mainly for anticholinergic toxicity and occasionally for glaucoma. It works by increasing acetylcholine concentrations in the central and peripheral nervous systems. This mechanism is unrelated to dopamine replacement or stimulation, making it inappropriate for first-line Parkinson’s disease management. C. Donepezil (Aricept) is used in the treatment of Alzheimer’s disease to improve cognition by increasing acetylcholine availability in the brain. It does not stimulate dopamine receptors or increase dopamine levels. Although Parkinson’s patients may later develop cognitive impairment, donepezil is not used as initial therapy for motor symptom control. D. Ropinirole (Requip) is a dopamine agonist that directly stimulates dopamine receptors in the brain, helping to improve motor symptoms of Parkinson’s disease. It is commonly used in early-stage disease, especially in younger patients, to reduce tremors, rigidity, and bradykinesia. Using dopamine agonists early may delay the long-term motor complications associated with levodopa therapy.